New Listing Registration (Form 8-A12B)

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-A

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

REVELATION BIOSCIENCES, INC.

(Exact name of Registrant as Specified in Its Charter)

(Former Name or Former Address, if Changed Since Last Report)

Securities to be registered pursuant to Section 12(b) of the Act:

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the following box. ☒

Securities to be registered pursuant to Section 12(g) of the Act: None

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1. Description of Registrant's Securities to be Registered.

The securities to be registered hereby are the preferred share purchase rights (the "Rights") of Revelation Biosciences, Inc. (the "Company"). The description of the Rights set forth under Item 1.01 of the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on July 13, 2026, and the Rights Agreement, dated as of July 10, 2026, between the Company and Continental Stock Transfer & Trust Co., as Rights Agent (filed as an exhibit thereto and incorporated herein by reference), are incorporated herein by reference. The foregoing description is qualified in its entirety by reference to the Rights Agreement.

Item 2. Exhibits.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned thereunto duly authorized.